{"product_id":"fortishealthcare-five-forces-analysis","title":"Fortis Healthcare Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eFortis Healthcare faces intense competitive rivalry and growing buyer power as patients seek value and convenience, while regulatory barriers and capital-intensive hospital operations limit new entrants but give suppliers moderate leverage; substitutes like telemedicine and standalone clinics pose emerging threats that could reshape margins and patient flows. This brief snapshot only scratches the surface—unlock the full Porter's Five Forces Analysis to explore Fortis Healthcare’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of High-End Medical Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe procurement of advanced diagnostic and surgical equipment for Fortis Healthcare is concentrated among a few global suppliers—GE Healthcare, Siemens Healthineers, and Philips—who together held ~60–70% of the global imaging and hospital equipment market in 2024. Fortis depends on these vendors for robotic surgery systems (costing $1–2.5M each) and 3T MRI\/CT suites, giving manufacturers strong pricing and delivery leverage. This supplier concentration limits Fortis’s bargaining power and raises switching costs and CAPEX exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of Highly Specialized Medical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bargaining power of top-tier surgeons and specialists is very high in India; elite clinicians often bring referral pools that can account for 20–35% of a hospital unit’s revenue, so Fortis must match competitive profit-sharing—often 30–40% for high-demand procedures—and invest in advanced theaters and equipment (MRI, robotic surgery) to retain them.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation in the Pharmaceutical Industry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsolidation among pharma giants raises supplier power: the top 10 global drugmakers held ~58% of global pharma revenue in 2024, letting them push prices for patented, life-saving drugs and oncology consumables.\u003c\/p\u003e\n\u003cp\u003eFortis Healthcare offsets this via bulk procurement across 35+ hospitals, yet patented oncology drugs (e.g., CAR-T, checkpoint inhibitors) leave little room to negotiate—these suppliers command margins north of 40%.\u003c\/p\u003e\n\u003cp\u003eResult: Fortis depends on a handful of suppliers for high-margin specialized treatments, increasing cost and clinical supply risk despite scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Costs of Specialized Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe supply chain for specialized consumables like implants and cardiac stents exposes Fortis Healthcare to global raw-material price swings and India's local price caps; e.g., the 2024 National List capped select stent prices up to 70% below earlier market rates, squeezing hospital margins.\u003c\/p\u003e\n\u003cp\u003eSuppliers keep leverage through proprietary specs and limited interchangeability across surgical systems, forcing Fortis to stock multiple SKUs and accept higher procurement complexity and costs.\u003c\/p\u003e\n\u003cp\u003eFortis must tightly negotiate contracts, use volume pooling, and drive in-house standardization to protect EBITDA, since consumables account for roughly 12–18% of procedure costs in private hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 stent caps reduced prices ~50–70%\u003c\/li\u003e\n\u003cli\u003eConsumables ≈12–18% of procedure cost\u003c\/li\u003e\n\u003cli\u003eNon-interchangeable SKUs raise inventory\/complexity\u003c\/li\u003e\n\u003cli\u003eVolume deals and standardization mitigate margin pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Critical IT and Digital Infrastructure Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Fortis Healthcare scales AI diagnostics and EHRs, dependence on niche health-tech vendors rises; 2024 vendor-led platforms handled an estimated 65% of clinical workflows at large Indian hospital chains.\u003c\/p\u003e\n\u003cp\u003eData migration and retraining push switching costs up—projects often exceed $1–3m and 6–12 months—so vendors capture long-term leverage via multi-year service contracts and mandatory updates.\u003c\/p\u003e\n\u003cp\u003eThat gives suppliers steady bargaining power, visible in 2023–24 vendor renewal rates above 80% for integrated systems.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e65% clinical workflow reliance (2024 estimate)\u003c\/li\u003e\n\u003cli\u003e$1–3m typical migration cost\u003c\/li\u003e\n\u003cli\u003e6–12 months average switch time\u003c\/li\u003e\n\u003cli\u003e80%+ vendor renewal rate (2023–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier dominance squeezes margins: imaging, pharma, surgeons and stent cuts bite profits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high: 3 vendors (GE, Siemens, Philips) held ~60–70% of imaging equipment market in 2024, raising CAPEX and switching costs; top surgeons generate 20–35% of unit revenue with 30–40% profit-share demands; top 10 drugmakers held ~58% of pharma revenue in 2024, limiting negotiation on patented oncology drugs; consumables are ~12–18% of procedure costs and 2024 stent caps cut prices ~50–70%, squeezing margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging vendors\u003c\/td\u003e\n\u003ctd\u003e60–70% market share (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon revenue contribution\u003c\/td\u003e\n\u003ctd\u003e20–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon profit share\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop drugmakers\u003c\/td\u003e\n\u003ctd\u003e58% pharma revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e12–18% procedure cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStent price caps\u003c\/td\u003e\n\u003ctd\u003e−50–70% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Fortis Healthcare, evaluating competitive rivalry, buyer and supplier power, substitution threats, and entry barriers to reveal strategic pressures on pricing, margins, and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Fortis Healthcare Porter's Five Forces summary—clearly highlights supplier, buyer, entrant, substitute, and rivalry pressures for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Health Insurance and Third-Party Administrators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rise in Indian health insurance penetration—retail plus group surged to ~39% of the population in 2024 per IRDAI and gross direct premiums grew 16% to ₹2.3 trillion in FY2024—shifts bargaining power to insurers and TPAs, who press Fortis for bulk rates and standardized packages. Fortis’ pricing freedom narrows as insurers negotiate bundled tariffs and pre-approved packages; cashless claims now account for ~65% of hospital admissions, forcing adherence to payer-set rates. This compresses margins on high-volume procedures and raises revenue volatility tied to insurer contract renewals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Price Sensitivity in the Indian Middle Class\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh price sensitivity in India’s middle class means many patients shop around: 2024 data shows out-of-pocket payments still cover ~52% of health spending, so Fortis faces direct comparison with Apollo Hospitals and Max Healthcare on elective-procedure pricing; online platforms list procedure rates, pushing Fortis to balance premium services with competitive tariffs—Fortis reported 2024 ARPOB (average revenue per occupied bed) pressure as volumes rose but pricing growth slowed to ~4% year-on-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for General Healthcare Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor primary care, routine diagnostics, and minor surgeries patients face very low switching costs, with over 70% of urban Indians willing to change hospitals for convenience or shorter waits per 2023 Kantar Health data; metros like Delhi and Mumbai have 4–8 competing hospitals per 100,000 people, forcing Fortis Healthcare to sustain high patient engagement and service metrics—average outpatient NPS must exceed 50 and same-day admission rates improve to keep loyalty and protect revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Government Health Schemes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAyushman Bharat (PM-JAY) covers ~560 million Indians and sets capped procedure rates, giving the state high bargaining power over Fortis by pressuring margins; in FY2024 Fortis reported ~12% revenue from govt schemes, so rate caps materially affect profitability.\u003c\/p\u003e\n\u003cp\u003eFortis must cut average length of stay, raise bed turnover, and negotiate bulk supply contracts to sustain margins while participating in PM-JAY networks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePM-JAY covers ~560M people\u003c\/li\u003e\n\u003cli\u003eFortis FY2024 ~12% revenue from govt schemes\u003c\/li\u003e\n\u003cli\u003eRate caps reduce per-case margins\u003c\/li\u003e\n\u003cli\u003eOperational efficiency and supply deals are key\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to Information and Digital Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern patients use online reviews and outcome data—India reports 70% of hospital seekers check ratings (2024 RedSeer survey)—so information symmetry weakens traditional hospital authority and shifts bargaining power to patients.\u003c\/p\u003e\n\u003cp\u003eFortis must sustain public ratings and publish success rates; Fortis Healthcare reported 78% patient satisfaction and 65% occupancy in FY2024, raising pressure to improve visible outcomes to retain fee-for-service revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e70% check ratings (RedSeer 2024)\u003c\/li\u003e\n\u003cli\u003eFortis FY2024 satisfaction 78%\u003c\/li\u003e\n\u003cli\u003eOccupancy 65% FY2024\u003c\/li\u003e\n\u003cli\u003eHigher transparency = pricing and service demands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovt schemes, cashless care \u0026amp; slower ARPOB squeeze hospital margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsurers, PM-JAY, and informed patients have strong bargaining power—cashless claims ~65%, PM-JAY covers ~560M, Fortis FY2024 ~12% revenue from govt schemes, ARPOB growth slowed to ~4% YoY—forcing tariff caps, bulk-rate negotiation, and efficiency drives that compress margins on high-volume care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCashless admissions\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePM-JAY coverage\u003c\/td\u003e\n\u003ctd\u003e~560M people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFortis rev from govt\u003c\/td\u003e\n\u003ctd\u003e~12% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARPOB growth\u003c\/td\u003e\n\u003ctd\u003e~4% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOccupancy\u003c\/td\u003e\n\u003ctd\u003e65% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eFortis Healthcare Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Fortis Healthcare Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is a professionally written, fully formatted section of the full report and is ready for download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're looking at the actual deliverable; once you complete your purchase, you’ll get instant access to this same file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747051450745,"sku":"fortishealthcare-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/fortishealthcare-five-forces-analysis.png?v=1772194623","url":"https:\/\/growthsharematrix.com\/products\/fortishealthcare-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}